Shanghai Sincere Bio's DLL3-Targeted CAR-T Therapy SNC115 Receives IND Acceptance with Promising IIT Clinical Data

RecentlyDay，Simnova Submits TargetedDLL3Chimeric Antigen Receptor Gene-ModifiedTCell Injection (SNC115) Clinical trial application approved by the Center for Drug Evaluation of the National Medical Products Administration (CDE) Acceptance，Indications are for recurrent or refractory small cell lung cancer and/Or other neuroendocrine cancers. 

SNC115An investigator-initiated clinical study is currently underway. (IIT), the main purpose is to preliminarily evaluateSNC115Injection in relapsed or refractory small cell lung cancer (SCLC）/Safety and Pharmacokinetics in Patients with Large Cell Neuroendocrine Carcinoma of the Lung (PK) Characteristics.

Currently available5ExampleSCLCThe patient has received the infusion.SNC115`, with doses of`DL1=1×10⁵ CAR+TCell/kg（N=1），DL2=3×10⁵CAR+TCell/kg（N=3），DL3=3×10⁶ CAR+TCell/kg（N=1). This5All cases have previously undergone at least2～6Patients with extensive-stage small cell lung cancer who failed systemic therapy. During reinfusionSNC115Later Only1Example: Patients Appear1Grade Cytokine Release Syndrome (CRS), rapid recovery was observed after treatment with tocilizumab, and no dose-limiting toxicity (DLT）、Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS`) and Serious Adverse Events (`SAE）。

In5Among the patients whose efficacy can be evaluated,DL1of1The patient's condition is stable.(SD)；DL2The three patients were partially relieved (PR）1Example, Stable Disease (SDReduce)1Example, Disease Progression1Example (DLL3Expression<1）； DL3A case of a patient isPR。DL2AndDL3of patientsPKDetectedCARCopy number, indicating that at this doseCAR-TCells show detectable amplification in vivo.

SNC115Preliminary data demonstrate good safety and show positive clinical efficacy signals in third-line and beyond patients. The safety and efficacy of higher doses are still being explored.

SNC115AdoptThe innovative design of the proprietary armored structure has demonstrated superiority over similar products in preclinical studies.CARDesign more effective activity. Meanwhile, Simnova has mature and stable cell preparation.CMCAbility, significantly reducedTThe in vitro expansion time of cells reduces the waiting time for preparation for patients, which is more significant for patients with advanced tumors.

About Simnova

Simnova is a cell therapy biotechnology company at the clinical development stage. Founded in2019Year, originally a subsidiary of Simnova,2021Year split into an independently operated company. Simnova has research centers in Shanghai, China, and Boston, USA. The company is currently focusing on developing globally competitive universal-typeCAR-NK, and is also actively promoting clinical research on in vivo cell therapy. Simnova collaborates with star biotechnology companiesORNA's collaboration has laid out a strategy based on circularmRNAand the development of next-generation universal in vivo cell therapy products with targeted delivery platforms; simultaneously self-developed lentivirus-based in vivoCAR-TIt is about to enter the clinical validation stage. This technology will becomeCAR-NKAnother disruptive universal cell therapy drug format with significant potential for wide application in treating tumors, autoimmune diseases, and other disease areas.

In order to allow everyone to learn and communicate with each other better,WeChat Official Account "Cell Gene Therapy" TeamA WeChat communication group for cell therapy and gene therapy has been established. Interested friends can scan the QR code below to add the editor's WeChat and join the cell therapy and gene therapy communication group.。